Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PD-0325901 (mirdametinib) is an investigational MEK inhibitor. It is being evaluated in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Lead Product(s): Mirdametinib
Therapeutic Area: Oncology Product Name: PD-0325901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Ogsiveo (nirogacestat) is a USFDA approved oral, selective, small molecule gamma secretase inhibitor. It is being evaluated for the treatment of adults with desmoid tumors.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $316.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Details:
The net proceeds will be used to support commercialization of Ogsiveo (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment and continued research and development activities.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Ogsiveo (nirogacestat) is an investigational gamma secretase inhibitor which is approved by USFDA as the first and only treatment for adults with desmoid tumors.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: Ogsiveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
PD-0325901 (mirdametinib) is an investigational MEK inhibitor. It is being evaluated in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Lead Product(s): Mirdametinib
Therapeutic Area: Oncology Product Name: PD-0325901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with treatment of adults with desmoid tumors. PDUFA date has been extended by the standard extension period of three months.
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
PF-03084014 (nirogacestat) is an investigational gamma secretase inhibitor being develop in patients with recurrent ovarian granulosa cell tumors (OvGCT).
Lead Product(s): Nirogacestat
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023